Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-wiskostatin is a small molecule inhibitor that selectively targets neuronal Wiskott-Aldrich syndrome protein (N-WASP), a key regulator of actin polymerization and cytoskeleton dynamics. It acts by binding to the regulatory GTPase-binding domain of N-WASP, stabilizing its autoinhibited conformation, and thereby preventing activation by Cdc42 and phosphatidylinositol 4,5-bisphosphate (PIP2). This inhibition blocks the downstream activation of the Arp2/3 complex, resulting in reduced actin filament nucleation. The compound has been widely used as a research tool to study actin-dependent cellular processes such as cell motility, membrane trafficking, dendritic spine formation, and synaptic development[3][7][9]. Its primary use is experimental; it is not approved for clinical or therapeutic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-wiskostatin.